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Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease
that is most commonly found in children from West and Central Africa. Despite the severity
of the infection, therapeutic options are limited to antibiotics with severe side effects. Here,
we show that M. ulcerans is susceptible to the anti-tubercular drug Q203 and related com-
pounds targeting the respiratory cytochrome bc1:aa3. While the cytochrome bc1:aa3 is the
primary terminal oxidase in Mycobacterium tuberculosis, the presence of an alternate bd-type
terminal oxidase limits the bactericidal and sterilizing potency of Q203 against this bacter-
ium. M. ulcerans strains found in Buruli ulcer patients from Africa and Australia lost all
alternate terminal electron acceptors and rely exclusively on the cytochrome bc1:aa3 to
respire. As a result, Q203 is bactericidal at low dose against M. ulcerans replicating in vitro
and in mice, making the drug a promising candidate for Buruli ulcer treatment.
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Mycobacterium ulcerans is the causative agent of Buruliulcer (BU), a chronic necrotizing infection of the skinand the underlying tissue1. BU has been reported in
more than 30 countries worldwide, but affects predominantly
populations in West and Central Africa2, and is emerging in
Australia3. Genomic analyses have shown that M. ulcerans has a
common ancestor with Mycobacterium marinum4, a ﬁsh patho-
gen that occasionally causes granulomatous skin lesions in
humans5. The ancestor of M. ulcerans acquired a virulence
plasmid that carries the genes encoding the enzymatic machinery
required for the synthesis of the cytotoxic macrolide toxin
mycolactone6, which plays a key role in the chronic necrotizing
pathogenesis of BU7–9. Mycobacterium ulcerans has subsequently
undergone reductive evolution to become a niche-adapted
organism with a 0.8 Mb smaller genome than M. marinum, and
harbouring several hundred pseudogenes10. Two major lineages
have been distinguished among M. ulcerans strains isolated from
human BU lesions11. While the ancestral lineage found in
patients from Asia, South America and Mexico is associated only
sporadically with disease in humans, local incidence rates for BU
caused by classical lineage strains in Africa and Australia can be
as high as 1/200 per year12.
Until recently, antibiotic therapy of BU was thought to be
ineffective, and wide surgical excision of BU lesions was the
treatment of choice. Based on results with an experimental mouse
infection model for BU, an 8 weeks daily treatment with rifam-
picin and streptomycin was clinically tested and implemented as
standard of care13,14. Despite clinical efﬁcacy15, nephrotoxic,
hepatotoxic and ototoxic side effects16,17 combined with the
requirement for daily injections advocate for alternative treat-
ments. Repurposing of new tuberculosis drug candidates is an
attractive approach to search for new treatment options for BU.
However, most tuberculosis-active scaffolds have no, or limited
activity against M. ulcerans18. Here, we show that reductive
evolution drove the exquisite susceptibility of M. ulcerans to the
imidazopyridine carboxamide (IPA) compound Q20319, a
clinical-stage drug candidate for tuberculosis that targets the
respiratory cytochrome bc1:aa3 (cyt-bc1:aa3). Recently, we
demonstrated that the presence of the cytochrome-bd oxidase
(cyt-bd), an alternate bd-type terminal oxidase, limits the ster-
ilizing potency of Q203 in Mycobacterium tuberculosis20.
M. ulcerans strains belonging to the classical lineage from African
and Australian origin lost all terminal electron acceptors except
the cyt-bc1:aa3, revealing the vulnerability of this target to che-
mical inhibition that can be exploited to develop potent drugs for
BU.
Results
Cyt-bd is inactive in classical M. ulcerans. Comparison of the
sequences of the cyt-bd-encoding genes cydAB of M. tuberculosis,
M. marinum and M. ulcerans revealed the presence of a nonsense
mutation in the cydA sequences of the several 100 available
genomes of African and Australian M. ulcerans strains3,21–23. A
base substitution (692G>A) converted the tryptophan-encoding
codon TGG into a stop codon (W231X) (Fig. 1a). In contrast to
these classical lineage strains, the genomes of M. marinum and of
ancestral Japanese M. ulcerans strains24,25 harbour a cydA gene
encoding a full-length open-reading frame (Fig. 1a).
Functional assays were performed to verify the impact of the
cydAW231X mutation on the activity of the cyt-bd. We made use
of a M. bovis Bacillus Calmette–Guérin (BCG) strain deﬁcient in
the expression of cyt-bd (BCGΔcydAB), in which oxygen
consumption can be completely inhibited with drugs targeting
the cyt-bc1:aa320. The BCGΔcydAB strain was transformed with
the cydAB genes of either the classical or ancestral M. ulcerans
lineages. Upon treatment with the cyt-bc1:aa3 inhibitor Q203,
oxygen respiration was completely inhibited in the BCGΔcydAB
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Fig. 1 The cytochrome bc1:aa3 is the sole respiratory terminal oxidase in classical M. ulcerans strains. a A single-nucleotide polymorphism (692G>A)
converting the tryptophan-encoding codon TGG into the stop codon TAG is present in cydA of all classical M. ulcerans strains. b The cydAB operon present
in classical M. ulcerans strains does not encode a functional cyt-bd. Q203-treated M. bovis BCGΔcydAB strains complemented with the cydAB operon from
classical lineage, or from Japanese ancestral lineage strains were incubated with Q203 (100 nM) in sealed tubes containing 0.001% methylene blue used
as an oxygen sensor. Pictures were taken immediately after closing the tubes (day 0), and 5 days after incubation at 37 °C. Bedaquiline (1 mM) and DMSO
(−) were used as controls. c Oxidative phosphorylation pathway in classical M. ulcerans strains, the molecular targets of Q203 and bedaquiline (BDQ) are
shown
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strain (Supplementary Fig. 1), as shown before20. Oxygen
respiration was restored in the Q203-treated BCGΔcydAB strain
carrying the ancestral cydAB genes (Fig. 1b). Conversely,
complementation with the cydAB genes of classical strain origin,
having the cydA W231X mutation, failed to restore oxygen
respiration (Fig. 1b). As a control, the drug bedaquiline (Sirturo®)
that targets the mycobacterial F1Fo ATP synthase inhibited
oxygen consumption in both strains (Fig. 1b). These results
demonstrated that the cydA W231X polymorphism in the
classical M. ulcerans strains has led to the loss of function of
the cyt-bd. Furthermore, the genes encoding the anaerobic
electron terminal acceptor nitrate reductase (Supplementary
Fig. 2) and for fumarate reductase are missing in the genome of
M. ulcerans, indicating that the cyt-bc1:aa3 is the only functional
terminal electron acceptor in classical lineage M. ulcerans strains
(Fig. 1c). This is in contrast to the ancestral M. ulcerans lineage
and to M. tuberculosis that possess two and four terminal electron
acceptors, respectively (Supplementary Fig. 3).
Mycobacterium ulcerans is sensitive to drugs targeting the cyt-
bc1:aa3. TheM. ulcerans cyt-bc1 complex subunit QcrB has 90.3%
sequence identity with the M. tuberculosis counterpart, and
possesses an additional 10 residues, 206GGVGDDCTAA215,
located in an outside loop (Supplementary Fig. 4). Furthermore,
the residues for which substitutions are associated with resistance
to IPA compounds in M. tuberculosis19,26 are all conserved
(Supplementary Fig. 4). The comparison of the 3-dimensional
model of QcrB between M. tuberculosis and M. ulcerans revealed
an overall similar topology (Supplementary Fig. 5). The model
revealed that the additional 10-residue region in the M. ulcerans
QcrB is unlikely to inﬂuence the interaction between the target
and the IPA compounds. This is because the distance between the
region 206GGVGDDCTAA215 to all residues known to confer
resistance to IPA derivatives in M. tuberculosis is more than 25 Å,
a distance greater than the 13 Å length of Q203, one of the largest
IPA derivatives. These observations suggested that the lead
optimization of the IPA series that resulted in the anti-
tuberculosis drug candidate Q203 may also be valid for M.
ulcerans. Proﬁling of 87 IPA compounds for activity against the
classical M. ulcerans strain S1013 using a resazurin-based mini-
mum inhibitory concentration (MIC) assay (Table 1 and Sup-
plementary Table 1) revealed a comparable structure–activity
relationship to the trend observed in M. tuberculosis27. Small
residues such as halogen, methyl or ethyl were tolerated on the
imidazopyridine core, while the optimum activity of the sub-
stitution pattern depended on the amide residue (Supplementary
Table 1). Q203 was the most active derivative with an outstanding
minimum inhibitory concentration (MIC50) below 1 nM in all six
tested M. ulcerans classical lineage isolates of African and Aus-
tralian origin (Fig. 2a, b). Of note, two additional advanced
preclinical IPA drug candidates, ND-1088528 and ND-1117629,
were also potent against M. ulcerans (Table 1). The MIC50 values
of Q203 against Japanese ancestral lineage isolates encoding a
functional cyt-bd were 4- to 8-fold higher compared to the
classical strains (Fig. 2b). In contrast, classical and ancestral
lineage isolates were equally sensitive to bedaquiline (Fig. 2b).
The sub-nanomolar potency of Q203 against the classical lineage
and the reduced potency against the ancestral lineage was
reconﬁrmed using two assays determining directly the increase in
bacterial biomass for the prototype isolates S1013 (classical) and
S1325 (ancestral) (Fig. 2c, supplementary Fig. 6). Interestingly,
Q203 inhibited the growth of the ancestral strain only partially, as
witnessed by the high level of the bottom plateau in the optical
density-based assay (Fig. 2c), and the limited effect on the size of
the bacterial pellets in the pellet-formation assay (Supplementary
Fig. 6).
In contrast to M. tuberculosis, in which Q203 is only
bacteriostatic20, Q203 was bactericidal against the classical strain
S1013 replicating in vitro (Fig. 2d), conﬁrming that the absence of
an alternate bd-type terminal oxidase in the classical M. ulcerans
lineage sensitizes the bacterium to killing by Q203. To
demonstrate that IPA compounds kill M. ulcerans by inhibiting
oxidative phosphorylation, the effect of Q203 on oxygen
respiration was measured. Q203 treatment inhibited the oxygen
consumption rate (OCR) by 98.5% (Fig. 3a, b), whereas similar
treatment had limited effect against the ancestral strain S1325
that possesses a functional cyt-bd (Fig. 3b). The near-complete
inhibition of oxygen respiration in the classical strain S1013
correlated with a rapid and profound ATP depletion at a half-
maximal inhibitory concentration (IC50) of 670 pM, a concentra-
tion 100-fold lower compared to bedaquiline (Fig. 3c). ATP
depletion was rapid and sustained over time (Supplementary
Fig. 7). Conversely, Q203 had a limited effect on ATP levels in the
ancestral strain S1325 (Fig. 3d). The IPA derivative ND-11176
inhibited the OCR (Fig. 3a) and ATP synthesis (Fig. 3c) in the
classical lineage strain S1013 to the same extent as observed with
Q203, showing that oxidative phosphorylation inhibition is not
restricted to Q203 but extends to other preclinical IPA drug
candidates. Together, these ﬁndings demonstrate that the absence
of a functional cyt-bd in classical M. ulcerans strains sensitized
the bacteria to drugs targeting the cyt-bc1:aa3 terminal oxidase.
Relying solely on the cyt-bc1:aa3 terminal oxidase to perform
oxidative phosphorylation, these strains are unable to reroute the
electron ﬂow to an alternate terminal electron acceptor, and to
mitigate the effect of Q203 as observed in M. tuberculosis20.
Q203 has a low propensity to select for resistance in vitro.
Propensity to elicit the development of spontaneous resistance is
a critical factor for the development of a novel antibacterial.
Mutant selection experiments on agar plates containing 10 nM of
Q203 determined the spontaneous rate of mutation in the range
of 5.6 × 10−9, indicating a very low probability of emergence of
resistant mutants. All the analysed resistant mutants (14/14) had
a non-synonymous single-nucleotide polymorphism in QcrB
leading to the amino acids substitutions T313A, M352V, M352T,
or W322C (Supplementary Table 2). Substitution of these amino
acids has been reported to confer resistance to Q203 or other IPA
derivatives in M. tuberculosis19,26. The escape mutant harbouring
the mutation M352T in QcrB was lost shortly after selection due
to its inability to grow in liquid broth medium. Sequencing of
cydA in the 13 other spontaneous-resistant mutants revealed that
the base substitution G692A was still present, suggesting that the
reversion to a functional cyt-bd under Q203 pressure has a low
probability to be selected (<4.0 × 10−10).
Q203 eradicates M. ulcerans infection in a mouse model. The
high activity of Q203 against classical M. ulcerans strains in vitro
translated into high treatment efﬁcacy in the well-established
mouse footpad infection model of BU. In a ﬁrst set of experi-
ments, the potency of Q203 was compared to that of rifampicin
or rifampicin+ streptomycin. Given the favourable pharmaco-
kinetic properties of Q20319 that were conﬁrmed in this study
(Supplementary Table 3), we estimated that Q203 at 0.5 mg/kg
body weight would be an appropriate dose to achieve high efﬁ-
cacy in vivo. Daily drug treatment was initiated 5 weeks after
infection with the classical African strain Cu00130, a time point at
which animals had developed a swelling of their inoculated
footpad. After 4 weeks of daily treatment (5 times per week; orally
for Q203 and rifampicin and sub-cutaneously for streptomycin),
the bacterial load in the animals treated with Q203 0.5 mg/kg
body weight was reduced by more than 99.99% compared to the
untreated control group (Fig. 4a). Furthermore, the bacterial load
in the food pad of Q203-treated animals was 1000-fold lower
compared to the group treated with rifampicin 10 mg/kg body
weight (Fig. 4a), showing that Q203 had a superior activity than
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rifampicin when given at a dose 20-fold lower. Furthermore,
Q203 at 0.5 mg/kg body weight was as good as the clinically used
drug combination rifampicin 10 mg/kg body weight+ strepto-
mycin 150 mg/kg body weight in reducing bacterial load at week
4 post treatment (Fig. 4a). After 8 weeks of daily treatment, Q203
had eradicated M. ulcerans infection in 90% (9/10) of the mice,
whereas only ﬁve colonies grew from the footpad lysate of the last
animal (Fig. 4a). This level of efﬁcacy at 8 weeks compared
favourably with the rifampicin and rifampicin+ streptomycin
treatment that eradicated infection in 75% (6/8) and 66.6% (6/9)
of the treated mice, respectively (Fig. 4a). Given the stability and
long half-life of Q20319, we next tested whether intermittent
administration of Q203 would resolve a BU infection in mice.
Five weeks after infection with the classical strain S1013, when the
mice started to show swelling of the infected feet (Fig. 4b),
treatment was initiated by oral administration of Q203 at 0.5 mg/
kg body weight three times per week for 4 weeks. During that
time, a strong increase in footpad thickness was observed for the
untreated control animals (Fig. 4b, c). Histopathological analyses
of footpads from these control animals revealed oedema
formation and massive tissue necrosis (Fig. 4d). Due to severe
progression of the pathogenesis, the control animals had to be
euthanized at week 9 post infection. In contrast, a complete
regression of the footpad swelling was observed in the Q203-
treated animals as early as 10 days after treatment initiation
(Fig. 4b). Footpad thickness in the Q203-treated mice returned to
normal levels (Fig. 4f) and did not increase further for the entire
observation period of 6 months post treatment (Fig. 4b). Strik-
ingly, the footpads of the Q203-treated mice were completely
devoid of oedema and tissue necrosis after completion of treat-
ment (Fig. 4g). While large extracellular clusters of solid-stained
acid-fast bacilli (AFB) embedded in the necrotic lesions were
observed in footpads of the untreated control mice (Fig. 4e), only
small numbers of AFB with beaded, not solid-stained appearance
were found in the Q203-treated mice at week 15 (Fig. 4h), indi-
cating loss of bacterial viability31. The absence of viable bacteria
in Q203-treated animals was conﬁrmed 5 weeks after completion
of treatment (Supplementary Fig. 8). Conversely, intermittent
administration of rifampicin at 10 mg/kg body was unable to stop
disease progression completely, as witnessed by continuing
Table 1 Activity of IPA derivatives against the classical M. ulcerans strain S1013
The potency of the IPA derivatives was tested in dose–response against M. ulcerans S1013 replicating in culture broth medium. Compounds 5, 13, 31 and 80 are representatives of different activity groups
listed in detail in Supplementary Table 1
*cLogP calculated with PerkinElmer ChemDraw Professional 16.0.1.4
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footpad swelling (Fig. 4b) and reﬂected by the presence of large
numbers of colony-forming units (CFU) 5 weeks after completion
of treatment in 5/8 mice (Supplementary Fig. 8). This result
illustrates the potential advantage of Q203 over drugs with a
shorter half-life to simplify BU treatment. It is interesting to note
that, whereas a dose of 0.5 mg/kg body weight of Q203 given
three times per week was sufﬁcient to eradicate a BU infection in
the mouse model, a dose of 2 mg/kg body weight administered
following a comparable regimen had no effect in an experimental
mouse model of tuberculosis20, conﬁrming the exceptional sus-
ceptibility of the classical lineage of M. ulcerans to the IPA
compounds.
Discussion
While traditionally surgical excision has been the only treatment
recommended for BU, the World Health Organization published
in 2004 a provisional guidance recommending a combination
therapy with daily administration of rifampicin and streptomycin
for a period of 8 weeks2. Despite clinical efﬁcacy, administration
of streptomycin through injections has a negative impact on
patient acceptance and adherence and is frequently associated
with permanent ototoxicity and nephrotoxicity16,17. Therefore,
replacement of streptomycin with oral clarithromycin is currently
considered by the World Health Organization (WHO) Technical
Advisory Group on BU. Rifampicin is currently the most effective
drug against M. ulcerans and essential for successful treatment. In
case of emergence of rifampicin resistance in M. ulcerans, no
antibiotics are currently available as substitutes. Our study indi-
cates that drugs targeting the respiratory cyt-bc1:aa3 are pro-
mising agents to treat BU. Strains of the classical M. ulcerans
lineage are exquisitely sensitive to Q203 because their respiration
relies exclusively on the cyt-bc1:aa3 terminal oxidase. Strains
belonging to the classical lineage are responsible for the BU foci
in Africa and Australia that are typically characterized by high
local prevalence12. In contrast, the ancestral lineage is responsible
for only scattered, sporadic BU cases recorded in Asia and the
Americas12. Of the 58,894 BU cases reported between 2002 and
2016, it is estimated that the vast majority (>97%) is caused by
classical lineage strains12 lacking a functional cyt-bd.
Ongoing reductive evolution has been associated with resis-
tance to anti-tubercular drugs due to possible loss of targets18 or
enzymes required for prodrug bio-activation32,33. This study
demonstrates that reductive evolution can drive hyper-
susceptibility to certain classes of drugs by eliminating meta-
bolic redundancy. In the particular case of the oxidative phos-
phorylation pathway, the loss of alternate terminal electron
acceptors makes the cyt-bc1:aa3 absolutely essential for survival,
and therefore an excellent drug target. The clinical-stage drug
Q203 has a strong bactericidal activity against classical
M. ulcerans strains both in vitro and in vivo, and could both
simplify and shorten BU treatment. In the mouse infection
model, oral administration of Q203 three times per week for
4 weeks was highly effective. Given the high potency and long
half-life of Q203, an even simpler treatment regimen may be
possible. It is interesting to note that since Q203 and bedaquiline
have a comparable long half-life, they could be combined to
develop a radically simpliﬁed treatment regimen for BU.
Together, our data demonstrate that drugs targeting the cyt-
bc1:aa3 complex, such as the IPAs, and exempliﬁed by the clinical
candidate Q203, are promising drug candidates for BU. The
natural loss of cyt-bd function argues that Q203 may have a
higher efﬁcacy and safety margin for BU treatment in Africa and
Australia than for tuberculosis treatment; assumptions that
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should be tested in human clinical trials. The concept may also
apply to Mycobacterium leprae, another mycobacterial species
that does not possess as well the cyt-bd-encoding genes34.
Methods
Bacterial strains and growth conditions. M. ulcerans strains were isolated from
BU lesions of patients from Cameroon (strains S1013, S1213 and S1298), Cote
d’Ivoire (Cu001), Australia (strains S1251, S1273 and S1231) or Japan (strains
S1324, S1325 and S1326). Bacteria were cultivated at 32 °C in BacT/Alert culture
bottles supplemented with enrichment medium (bioMérieux). For in vitro com-
pound testing, bacteria were grown either in Middlebrook 7H9 medium (Difco) or
in Middlebrook 7H10 agar (Difco), supplemented with 10% (vol/vol) Middlebrook
OADC supplement.
MIC50 determination. MIC50 was determined using a resazurin microtiter assay35.
Cultures were incubated at an initial optical density 600 nm (OD600) of 0.02 with a
dose range of antibiotics (2-fold dilution range) at 32 °C for 8 days. End-point
ﬂuorescence reading (Ex540 nm/Em588 nm) was done after incubation with 10% (vol/
vol) resazurin solution (0.125 mg/mL, Sigma) for 24 h. Alternatively, MIC50 was
determined by the broth microdilution method36 adapted for M. ulcerans. A
volume of 150 μl ofM. ulcerans culture (ﬁnal OD600 of 0.02) was added to each well
containing a dose range of antibiotics, and the assay plates were incubated at 32 °C
for 15 days. OD600 values were recorded using a Cytation 5 Cell Imaging Multi-
Mode Reader, and MIC50 curves were plotted using the GraphPad Prism
5 software.
MBC determination. M. ulcerans S1013 at an OD600 of 0.01 was incubated with
and without Q203 at 32 °C. Q203 potency was tested at a concentration of 1, 4 and
16 nM. Viability was determined by CFU determination on agar plates over a
period of 90 days.
Expression of the M. ulcerans cydAB operons in M. bovis BCG. Two com-
plementation plasmids were created by incorporating the cydAB genes from the
African or Japanese M. ulcerans strains into the pmv306 vector. The plasmids were
electroporated in the M. bovis BCGΔcydAB20. Transformants were selected on
7H10-OADC agar plates containing 20 µg/mL of kanamycin.
Oxygen consumption assays. The methylene blue assays and the MitoXpress
oxygen consumption assay were used to measure oxygen consumption in myco-
bacteria as described before20. Brieﬂy, mycobacteria were grown to an OD600 of 0.3
in Middlebrook 7H9 media. The cultures were washed twice and resuspended in
Middlebrook 7H9 medium without glycerol and incubated with Q203 (100 nM),
bedaquiline (1 µM), or 1% dimethyl sulfoxide (DMSO) (solvent control). The
cultures were then transferred to 2 mL glass tubes containing methylene blue at a
ﬁnal concentration of 0.001%. The tubes were closed tightly and incubated at 37 °C
for 5 days under anaerobic conditions to avoid oxygen leakage within the tubes.
Pictures were taken immediately after incubation, and 5 days post incubation.
For the MitoXpress oxygen consumption assay, M. ulcerans strain S1013 was
grown to an OD600 of 0.9 in Middlebrook 7H9-ADS medium. Cultures were pre-
incubated with Q203 (5 nM), streptomycin (5 µM) or 1% DMSO (solvent control)
for 6 h. One hundred and ﬁfty microliters of each culture were transferred to black,
clear-bottom 96-well plates containing 10 µL of the MitoXpress probe (MitoXpress
Xtra-Oxygen consumption assay, Luxcel Biosciences). Each well was overlaid with
high-sensitivity oil to prevent oxygen diffusion. Time resolved ﬂuorescence reading
(Ex380 nm/Em650 nm) was recorded on a BioTek Cytation 5 reader for 5 h. Lifetime
calculation of each condition was computed, and the OCR was determined from
the slope of the lifetime graphs.
Intracellular ATP quantiﬁcation. ATP levels were measured using the BacTiter-
Glo™ Microbial Cell Viability Assay (Promega). ATP levels were quantiﬁed at 24
and 72 h post treatment by adding an equal volume of Bactiter-Glo reagent.
Luminescence reading was recorded on a BioTek CYTATION 3 reader.
Mouse footpad infection model. Efﬁcacy testing by CFU determination. The
study was granted ethical approval by the animal welfare committee of the Sor-
bonne Universities, Faculté de Médecine Pierre et Marie-Curie (Authorization
Number: APAFIS 9576-2017030117176185 v2). Four- to six-week-old BALB/c
mice (Janvier Labs, Le Genest Saint-Isle, France) were inoculated in the left hind
footpad with 30 μL of a bacterial suspension containing 2 × 104 CFU ofM. ulcerans
Cu001. Seven weeks after inoculation, swelling in the inoculated footpad conﬁrmed
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Fig. 3 Inhibition of cyt-bc1:aa3 arrests oxidative phosphorylation in classical M. ulcerans. a Oxygen consumption rates in the classical lineage M. ulcerans
strain S1013 treated with Q203 (5 nM, red squares), ND-11176 (50 nM, purple diamonds), streptomycin (5000 nM, green triangles) or DMSO (1%, black
circles) was measured using the MitoXpress® Xtra-oxygen probe. Fluorescence (Ex380 nm, Em650 nm) was measured over 350min. The experiment was
performed in triplicate and repeated two times. b Effect of Q203 (5 nM) or streptomycin (5000 nM) treatment on the oxygen consumption rate in the
classical strain S1013 (dark grey bars) and the ancestral strain S1325. c, d Quantiﬁcation of intracellular ATP levels in the classical strain S1013 (c) or in the
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that the infection was well established. Mice were randomly allocated to one of the
either following groups: untreated control (receiving vehicle control only), Q203-
treated (0.5 mg/kg body weight), rifampicin (10 mg/kg body weight) or rifampicin
+ streptomycin (10 mg/kg body weight and 150 mg/kg body weight, respectively).
Q203 and rifampicin were administered daily (5 times per week for 8 weeks) by
oral dosing, whereas streptomycin was administered sub-cutaneously. Ten animals
per condition and per time point were sacriﬁced for CFU determination in their
infected footpad, unless less animal were available due to unforeseen conditions.
For the week 4 data point, only nine and eight animals could be processed for CFU
determination in the rifampicin and rifampicin+ streptomycin groups, respec-
tively, because the other animals died during the gavaging period. For the same
reason, only eight and nine animals could be processed for CFU determination in
the rifampicin and rifampicin+ streptomycin groups, respectively, at the week 8
data point. For CFU determination, the tissues from the infected footpad were
removed aseptically and homogenized in 2 mL Hank’s balanced salt solution. For
the treated groups, the entire volumes were spread on 10 Lowenstein–Jensen
medium tubes (0.2 mL of suspension per tube). For the untreated controls, footpad
homogenates were serial diluted and plated on Lowenstein–Jensen medium. The
tubes were incubated at 30 °C for 90 days before CFU determination.
Efﬁcacy testing of intermittent dosing by gross pathology and histopathology
analysis. The study was carried out in accordance with the Rules and Regulations
for the Protection of Animal Rights (Tierschutzgesetz SR455) of the Swiss Federal
Food Safety and Veterinary Ofﬁce. The protocol was granted ethical approval by
the Veterinary Ofﬁce of the county of Vaud, Switzerland (Authorization Number:
2657). Forty eight-week-old female BALB/c mice (Harlan) received an infection
inoculum of 6 × 103 classical M. ulcerans S1013 in a volume of 30 µL into the hind
left footpad. Mice were randomly assigned to either the untreated, Q203-treated, or
rifampicin-treated groups (12 animals per group). The course of infection was
followed by measurement of the footpad thickness with a calliper. Oral treatment
was started 5 weeks after infection. Four mice were euthanized at week 5 post
infection to determine the bacterial load in the inoculated footpad before treatment
initiation. Mice received for a period of 4 weeks on 3 days per week 0.5 mg/kg body
Q203 suspended in 20% D-α-tocopherol polyethylene glycol 1000 succinate (Sigma,
57688) in water containing 1% DMSO (Sigma, D2650), rifampicin, or the vehicle
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Fig. 4 Efﬁcacy of Q203 in the mouse footpad infection model of Buruli ulcer. a Bacterial loads were enumerated in the footpads of mice infected with M.
ulcerans Cu001 after 4 and 8 weeks of daily treatment. Q203, rifampicin (Rif) and streptomycin (Str) were used at 0.5, 10 and 150mg/kg body weight,
respectively. Q203 and rifampicin were administered orally, streptomycin was given by the sub-cutaneous route. Ten mice per group and per time point
were used. Data are expressed as mean ± s.d. Statistical analysis was performed using two-sided Mann–Whitney U test. b Footpad thickness was followed
over time after infection with M. ulcerans S1013 on day 0. Q203 and rifampicin were administered orally three times per week at 0.5 and 10mg/kg body
weight, respectively, for 4 weeks (starting from week 5; treatment interval is boxed). Mean values with standard deviation are shown. The single cross
symbol represents all 12 animals from the untreated group had to be euthanized at week 9 post infection due to severe disease progression. The double
cross symbol represents all remaining eight animals from the rifampicin-treated group had to be euthanized at week 15 post infection due to unfavourable
progression in the majority of the animals (5/8). c, f Appearance of infected foot at week 9 treated with the vehicle control (c) or with Q203 (f). Black
arrows shows the site of infection. d–g Oedema formation and tissue necrosis in footpads from untreated control animals (d) and complete lack of oedema
and tissue necrosis in Q203-treated animals (g) after completion of treatment at week 9. e–h Large extracellular clusters of solid-stained AFB embedded in
the necrotic lesions in footpads of the untreated mice (e) and small numbers of AFB with beaded, not solid-stained appearance in the Q203-treated mice
(h) at week 15. Scale bars: c, f: 1 cm; d, g: 80 μm; e, h: 200 μm; inlets in e, h: 10 μm
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control only. At week 4 post treatment (week 9 post infection), four animals for the
Q203- and rifampicin-treated groups, and the 12 animals from the untreated group
were euthanized for analysis. All the animals from the untreated group had to be
euthanized at this time point due to the severe progression of the infection. For
histopathological analysis, mouse feet were removed above the ankle, and ﬁxed at
room temperature during 48 h in 10% neutral-buffered formalin solution (Sigma).
The feet were decalciﬁed in formic acid bone decalciﬁer (ImmunocalTM, StatLab)
for 6 days at room temperature and subsequently transferred to 70% ethyl alcohol.
After dehydration and parafﬁn embedding, 5 μm thin sections were cut, de-
parafﬁnized, rehydrated, and stained according to WHO standard protocols
www.who.int/buruli/laboratory_diagnosis/en/ with haematoxylin/eosin (Sigma) or
Ziehl–Neelsen/methylene blue (Sigma). At week 15 post infection (week 6 post
treatment), four animals from the Q203-treated group and eight animals from the
rifampicin-treated groups were euthanized for CFU determination. All remaining
animals from the rifampicin-treated group had to be euthanized at this time point
due to unfavourable disease progression.
Selection of spontaneous Q203-resistant mutants. M. ulcerans S1013 was
spread onto 7H11-OADC agar plates containing 10 nM of Q203 and incubated at
32 °C for 10 weeks. Incubation of the plates for an additional 6 weeks did not yield
further colonies. Fourteen colonies, picked from different plates, were grown in
7H9-ADS-Glycerol-Tween 80 medium supplemented with 2 nM of Q203, and
subjected to sequencing of QcrB and cydA genes. The resistance phenotype to Q203
was conﬁrmed by testing susceptibility to a dose range of Q203.
Data availability
The data that support the ﬁndings of this study are available from the corre-
sponding authors upon reasonable request.
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